We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.39%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
+$177M
Cap. Flow
-$53.9M
Cap. Flow %
-1.89%
Top 10 Hldgs %
28.19%
Holding
216
New
12
Increased
42
Reduced
44
Closed
16

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$46M
2
DHR icon
Danaher
DHR
+$34.4M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$30.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$22.3M
5
DXCM icon
DexCom
DXCM
+$20M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$44.2M
2
MRK icon
Merck
MRK
+$39.7M
3
PFE icon
Pfizer
PFE
+$39.7M
4
ABBV icon
AbbVie
ABBV
+$24.5M
5
CNC icon
Centene
CNC
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.34%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
176
DELISTED
Esperion Therapeutics
ESPR
$1.08M 0.04%
41,577
– –
KPTI icon
177
Karyopharm Therapeutics
KPTI
$44.4M
$1.02M 0.04%
4,383
– –
BMY.RT
178
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$1.02M 0.04%
1,473,710
– –
RGNX icon
179
Regenxbio
RGNX
$659M
$984K 0.03%
21,700
– –
AERI
180
DELISTED
Aerie Pharmaceuticals
AERI
$901K 0.03%
66,688
– –
ACIU icon
181
AC Immune
ACIU
$231M
$888K 0.03%
171,813
– –
CYH icon
182
Community Health Systems
CYH
$417M
$875K 0.03%
117,735
– –
GRFS
183
Grifois
GRFS
$5.49B
$874K 0.03%
47,373
– –
OVID icon
184
Ovid Therapeutics
OVID
$474M
$861K 0.03%
372,733
– –
YARW
185
Yarrow Bioscience, Inc. Common Stock
YARW
$25.3M
$856K 0.03%
150
– –
UHT
186
Universal Health Realty Income Trust
UHT
$587M
$724K 0.03%
11,258
– –
CHCT
187
Community Healthcare Trust
CHCT
$506M
$702K 0.02%
14,900
– –
NHI icon
188
National Health Investors
NHI
$3.61B
$694K 0.02%
10,038
– –
ASRT
189
DELISTED
Assertio
ASRT
$587K 0.02%
27,372
– –
CRBP icon
190
Corbus Pharmaceuticals
CRBP
$174M
$517K 0.02%
13,783
– –
CBAY
191
DELISTED
Cymabay Therapeutics
CBAY
$506K 0.02%
88,102
– –
CLSD
192
DELISTED
Clearside Biomedical
CLSD
$453K 0.02%
11,022
– –
SPPI
193
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$391K 0.01%
114,670
– –
CLLS
194
Cellectis
CLLS
$279M
$324K 0.01%
11,955
-98,192
-89% -$2.2M
VTRS icon
195
Viatris
VTRS
$20.6B
$251K 0.01%
13,400
-997,354
-99% -$16.3M
ALR
196
DELISTED
AlerisLife Inc
ALR
$167K 0.01%
24,237
– –
ORKA
197
Oruka Therapeutics
ORKA
$5.92B
$130K ﹤0.01%
2,705
– –
CLDX icon
198
Celldex Therapeutics
CLDX
$3.07B
$124K ﹤0.01%
7,053
– –
BLCM
199
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$21K ﹤0.01%
6,000
– –
ACHC icon
200
Acadia Healthcare
ACHC
$2.95B
– –
-131,200
Closed -$3.87M
5 6 7
8
9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Tekla Capital Management held 216 positions worth $2.85B, up 6.6% from $2.67B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Tekla Capital Management's Q4 2020 filing shows 12 new, 42 increased, 44 reduced and 16 closed positions. Its largest new stake was Teladoc Health: 56,520 shares worth $11.3M. The largest sale was Amgen, an estimated $44.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2020 buy was Teladoc Health: 56,520 shares worth $11.3M.
  • Tekla Capital Management added most to Thermo Fisher Scientific in Q4 2020, an estimated $46M increase.
  • Tekla Capital Management's biggest Q4 2020 reduction was Amgen, cutting an estimated $44.2M.
  • Tekla Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $19M.
  • Tekla Capital Management's ten largest holdings make up 28% of its $2.85B portfolio in Q4 2020.
  • Tekla Capital Management opened 12 new positions and closed 16 in Q4 2020.
  • Tekla Capital Management's portfolio value rose 6.6% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.